)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Intellia Therapeutics
Intellia Therapeutics (NTLA) investor relations material
Intellia Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Feb, 2026
Executive summary
Achieved rapid enrollment in key phase 3 trials for ATTR amyloidosis (MAGNITUDE, MAGNITUDE-2) and hereditary angioedema (HAELO), with HAELO enrollment completed ahead of schedule and positive long-term Phase 1/2 data for lonvo-z and nex-z.
FDA clinical hold on MAGNITUDE and MAGNITUDE-2 due to liver enzyme elevations was partially resolved; MAGNITUDE-2 hold lifted with protocol amendments, while MAGNITUDE remains on hold pending further FDA review.
Strong patient and physician interest in lonvo-z, with market research indicating high willingness to adopt the therapy if approved.
Commercial readiness for lonvo-z is advancing, with field teams, payer engagement, and launch strategies in place; U.S. launch targeted for first half of 2027.
Presented positive clinical data for both lonvo-z and nex-z at major scientific meetings in Q4 2025.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $605.1 million as of December 31, 2025, down from $861.7 million a year earlier.
Collaboration revenue for Q4 2025 was $23 million, up from $12.9 million in Q4 2024, driven by contract terminations and increased cost reimbursement.
R&D expenses decreased to $88.7 million in Q4 2025 from $116.9 million in Q4 2024, mainly due to lower employee and material costs, partially offset by higher lonvo-z clinical trial expenses.
Net loss for Q4 2025 was $95.8 million, a significant improvement from $128.9 million in the prior-year quarter; full-year net loss was $412.7 million versus $519.0 million in 2024.
Operating loss for Q4 2025 was $98.7 million, compared to $136.4 million in Q4 2024.
Outlook and guidance
Cash runway expected to extend into the second half of 2027, covering key milestones including MAGNITUDE-2 enrollment completion and lonvo-z launch.
Top-line data for lonvo-z phase 3 HAELO trial anticipated mid-2026, with BLA submission planned for the second half of 2026 and U.S. launch targeted for first half of 2027.
MAGNITUDE-2 expected to complete enrollment in the second half of 2026; MAGNITUDE resumption pending FDA clearance.
What is the expected path forward for MAGNITUDE?
How does market research inform lonvo-z launch strategy?
What drives the Q4 2025 R&D expense reduction?
Lonvo-z: how to differentiate from new HAE therapies?
How to predict nex-z liver injury pre-dosing?
Expense trajectory post-lonvo-z launch?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Intellia Therapeutics earnings date
TD Cowen 46th Annual Health Care Conference3 Mar, 2026
Intellia Therapeutics
Next Intellia Therapeutics earnings date
TD Cowen 46th Annual Health Care Conference3 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's therapies are based on a targeted genome editing platform, including CRISPR/Cas9 and proprietary next-generation programmable nucleases (PNs), which can induce a range of large deletions, substitutions or insertions across a target gene. The CRISPR/Cas9 genome editing technology has been shown to be effective in editing genomes in multiple cell types and organisms. Intellia Therapeutics was founded in 2013 and is based in Cambridge, Massachusetts.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage